

Altered Heterogeneity of Ageing Lung Endothelium is a Hallmark of Idiopathic Pulmonary Fibrosis

Eamon C. Faulkner¹, Adam A. Moverley², Simon P. Hart^{3*} and Leonid L. Nikitenko^{1*}

¹ Centre for Biomedicine, Hull York Medical School, University of Hull.

² Department of Cell and Developmental Biology, University College London.

³ Respiratory Research Group, Hull York Medical School, University of Hull.

*These authors share senior authorship.

Corresponding author:

Leonid L. Nikitenko PhD DSc, Room 202, Allam Building, Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX. Tel +44(0)1482 462062; leonid.nikitenko@hyms.ac.uk

Running title:

Heterogeneity of ageing endothelium in IPF.

Keywords:

Ageing lung, endothelial cell, idiopathic pulmonary fibrosis, lymphatic, single cell RNA sequencing.

Supplementary information:

Additional files 1-4.

1 **Abstract**

2

3 **Background**

4 Older age is the main risk factor for chronic lung diseases including idiopathic pulmonary
5 fibrosis (IPF). Halting or reversing progression of IPF remains an unmet clinical need due to
6 limited knowledge of underlying mechanisms. The lung circulatory system, composed of
7 blood (pulmonary and bronchial) and lymphatic vessels networks, has been implicated in IPF
8 pathophysiology in elderly people, based solely on reports of altered density and increased
9 permeability of vessels.

10 **Aim**

11 We aimed to define heterogeneity and IPF-associated changes of lung endothelial cells (EC
12 or endothelium) by comparing gene expression in tissues from elderly people - transplant
13 donors and recipients with IPF.

14 **Methods**

15 Single-cell RNA sequencing (scRNAseq) datasets of “ageing lung” tissues were selected only
16 from those publicly available sources that contain age-matching samples for both groups (49-
17 77 years old donors and IPF patients; nine pairs in total), integrated and compared. Findings
18 were validated by immunohistochemistry using EC-specific markers.

19 **Results**

20 The generation of integrated single-cell maps of ageing lung tissues revealed 17
21 subpopulations of endothelium (12 for blood and 5 for lymphatic vessels, including 9 novel),
22 with distinct transcriptional profiles. In IPF lung, the heterogeneity of ageing lung
23 endothelium was significantly altered - both in terms of cell numbers (linked to disease-
24 related changes in tissue composition) and differentially expressed genes (associated with
25 fibrosis, inflammation, differentiation and vasodilation) in individual pulmonary, bronchial
26 and lymphatic EC subpopulations.

27 **Conclusions**

28 These findings reveal underappreciated extent of heterogeneity and IPF-associated changes of
29 ageing lung endothelium. Our data suggest direct involvement of specific subpopulations of
30 ageing lung endothelium in IPF pathophysiology, uncovering cellular and molecular targets
31 which may have potential diagnostic, prognostic and therapeutic relevance. This study creates
32 a conceptual framework for appreciating the disease-specific heterogeneity of ageing lung
33 endothelium as a hallmark of IPF.

34

35 **Background**

36 Increasing age is the main risk factor for diagnosis and prognosis of major non-
37 communicable lung diseases, including lung cancer, chronic obstructive pulmonary disease
38 (COPD) and idiopathic pulmonary fibrosis (IPF) [1, 2]. IPF is the most common, progressive
39 and lethal interstitial lung disease with a prevalence of 33 to 450 per million people globally
40 [3]. IPF progression leads to declining quality of life, respiratory failure and eventually lung
41 transplantation or death. While the number of older people suffering from this disease is
42 steadily increasing and histopathological pattern of usual interstitial pneumonia (UIP),
43 hallmarks of ageing, particularly cellular senescence and extracellular matrix (ECM)
44 dysregulation, are prominent in the IPF lung, the aetiology of this disease remains unclear [2,
45 4-7]. Detailed understanding of cellular and molecular mechanisms underlying IPF-
46 associated changes in ageing human lung will be essential for diagnostics or prognostics of
47 IPF, and for developing effective therapies to halt or reverse disease progression.

48 Several lines of evidence implicate a role for the circulatory system, composed of blood
49 (pulmonary and bronchial) and lymphatic vessel networks, in IPF [7-18]. Some studies report
50 structural or functional changes in blood or lymphatic vessels, which are lined with a
51 monolayer of endothelial cells (EC or endothelium), although often without a comparison
52 between IPF patients and age-matched controls [10, 15, 17]. The precise contribution of
53 specialized lung vessel subtypes [19, 20] and distinct EC subpopulations that comprise them
54 to the pathophysiology and progression of IPF remain insufficiently characterized [21, 22].

55 Recent advances in single-cell RNA sequencing (scRNAseq) [23] have allowed
56 characterisation of cellular heterogeneity in healthy and diseased lung, resulting in the
57 generation of a human lung cell atlas (HLCA; [22]) and the IPF cell atlas [24]. Studies of
58 heterogeneity of human lung endothelium have reported up to nine subpopulations of EC in
59 healthy and/or diseased lung [22, 25, 26]. These reports utilised data from either a diverse
60 population of subjects (patients with COPD, IPF or other lung diseases, commonly placed

61 together for comparison) with a range of ages (varying from 21 to 80 years in some cases),
62 ethnicities and tobacco smoker statuses, or used samples from different areas of the lung, e.g.
63 distal lung parenchyma [27], longitudinal sections [25] or multiple lobes [28]. One recent
64 study generated a cell atlas of ageing lungs in COPD, comparing age-matched healthy
65 subjects and patients, and identifying 6 subpopulations of EC [21]. However, currently there
66 is still a major gap in knowledge about properties and roles of individual cell subpopulations
67 composing ageing human lung endothelium in other chronic lung diseases, including IPF.
68 Our report is the first to define (characterize, compare and contrast) the heterogeneity and
69 disease-associated changes of ageing lung endothelium in IPF patients and age-matched older
70 healthy subjects.

71

72 **Results**

73

74 **Integrated Single Cell Map of Ageing Human Lungs Displays Endothelial Cell** 75 **Contribution in Disease**

76 To characterise ageing human lung endothelium in IPF and to account for its intra- and
77 inter-lung heterogeneity within and between individuals [29], we performed comparative
78 analysis of scRNAseq data from lung tissue samples selected only from age-matched (63± 14
79 years old) transplant donors and recipients with IPF. Specifically, we selected data from only
80 those studies (cohorts) that contained samples for both conditions (transplant donors and IPF
81 patients). From all publicly available scRNAseq datasets of human IPF lungs (4 in total, to
82 our knowledge; [25, 27, 28, 30, 31]), only two, representing independent cohorts of
83 subjects/individuals of different ethnic backgrounds, with controlled sample locations,
84 fulfilled these selection criteria [25, 27] and therefore were used for generating a single
85 dataset of ageing human lungs for integrative comparative scRNAseq analysis (Table 1;

86 Figure 1A; for full details on dataset selection see Additional file 1: Detailed methods /
87 Dataset Selection).

88 The integration of the two datasets resulted in generation of a multi cohort single cell map
89 revealing 25 distinct populations (Figure 1A-B, Additional file 2: Figure S1), based on
90 specific gene expression patterns (Figures 1C, Additional file 2: Figure S2, Additional file 3:
91 Table S1) that include known cell type-specific transcriptomic markers [22, 25-27]. Identities
92 of two closely related blood and lymphatic vessel EC (BEC and LEC respectively)
93 populations (Figure 1B) were confirmed by detailed analysis of expression of a panel of pan-
94 EC and lymphatic EC-specific markers (Figure 1D).

95 Quantitative analysis of cell numbers for each of 25 populations in age-matched groups
96 revealed IPF-associated changes in ageing human lungs in both cohorts (Figure 1E). The
97 analysis reflected differences in location of tissue samples (Table 1), matching contribution
98 of different cell types to the total human lung cell population and alterations in IPF lung
99 reported in age non-matching studies [21, 22, 25-27, 30, 32] (Additional file 3: Table S2).
100 Also, it uncovered statistically insignificant changes in proportions of ageing human lung
101 BEC and LEC populations between cohorts and conditions (Figure 1E, Additional file 3:
102 Table S3), which is in agreement with similar analysis in age non-matching study of IPF
103 lungs [25]. Data integration revealed comparable spatial profiles of ageing human lung EC
104 populations in two conditions and two cohorts (Figure 1F) and their similar contribution in
105 donors and IPF patients (Figure 1G).

106

107 **Blood Vessel Endothelium in Ageing Human Lung Exhibits Disease-Specific** 108 **Heterogeneity and Alterations in Cell Numbers of Individual Subpopulations**

109 Unsupervised clustering of ageing human lung BEC alone (n=3192) identified 12 distinct
110 subpopulations (Figures 1A, 2A) based on their differentially expressed genes (DEG; Figures
111 2B, Additional file 2: Figure S3). Expression analysis of pan-EC markers and LEC-specific

112 genes confirmed their identities as BEC (Figure 2C). The analysis of top 10 DEG for each
113 subpopulation (110 in total) determined their selection for inclusion (or not) in 10 signatures
114 of ageing human lung BEC subpopulations (Figures 2B, D, Additional file 2: Figure S3, S4;
115 Additional file 3: Figure Table S4). 49 selected subpopulation-specific DEG contribute to
116 distinct transcriptional profiles for subpopulations 1-4 and 6-11 (Figure 2D). Subpopulations
117 zero and 5 lack obvious markers or signatures (Figures 2D, Additional file 2: Figure S5).

118 Expression analysis of the 49 subpopulation-specific DEG (Figure 2D) in the total lung
119 revealed that the majority of them were not EC-specific, i.e. also expressed in other cell types
120 (Additional file 2: Figure S4A). 39 of them have not been previously assigned as markers of
121 8 generic subpopulations of BEC identified and characterised earlier in human or mouse lung
122 [21, 22, 25, 26, 33], and thus are newly associated with ageing human lung endothelium
123 (Figure 2D; Additional file 2: Figure S4A, B). A pathway analysis uncovered their belonging
124 to specific classes of proteins, including secreted molecules, cell surface receptors,
125 transcription factors and sub-cellular distribution (Additional file 2: Figure S4B-C).

126 Three-dimensional pseudo-time lineage analysis revealed close relationships between
127 identified BEC subpopulations (Figure 2E; Additional file 4: Video S1). This included a
128 direct link between subpopulations 5 and 3, and manifestation of subpopulation zero as a
129 “convergence point” for seven subpopulations - 1, 2, 4, 6, 9, 10, 11 and, partially, 8. The
130 expression analysis of markers of EC sub-types proposed in other transcriptional studies in
131 human and murine lungs [21, 26, 33-38] was applied to 12 ageing human lung BEC
132 subpopulations identified in our study, and revealed only few distinct “marker / ageing
133 human lung BEC subpopulation” matches (Additional file 2: Figures S6, S7). Further
134 exploration of identities of 12 subpopulations by using these markers and also those proposed
135 for specific EC subpopulations in HLCA and IPF cell atlas studies [21, 22, 24-26], when
136 coupled with module scoring (Figure 2F) and cell cycle (Additional file 2: Figure S8)
137 analyses, confirmed these findings, whilst 4 subpopulations (zero, 5, 10 and 11) remained un-

138 matched (Figures 2F). Finally, quantitative analysis revealed a significant increase in
139 representation of two subpopulations (1 and 2) and overall decrease in subpopulation 7 in IPF
140 (Figure 3A-C; Additional file 3: Tables S5, S6), with specificity by the cohort (Figure 3D).

141

142 **Annotation of Blood Vessel Endothelial Cell Subpopulations and Identification of** 143 **Dedifferentiated Cells in Ageing Human Lung**

144 Altogether, our findings formed the foundation for the annotation of 12 ageing human lung
145 BEC subpopulations with distinct transcriptional signatures (Figure 4A; in-depth description
146 is provided in Additional file 1: Detailed methods, Annotation of BEC subpopulations).
147 Integrative analysis revealed that ageing human lung BEC belong to three and 8
148 subpopulations of bronchial and pulmonary circulation networks respectively (with one,
149 inflammatory, being “intermediary” as also identified in other reports [24]), and include two
150 previously undescribed subpopulations - designated as “de-differentiated” endothelium - in
151 pulmonary circulation (Figures 4A, 2F, Additional file 2: Figure S9). Ten subpopulations of
152 ageing human lung BEC have distinct transcriptional signatures, whilst no obvious DEG
153 could be identified for subpopulations zero and 5 (Figures 2B, 2D, 4A, Additional file 2:
154 Figures S5, S11; in-depth description is provided in Additional file 1: Detailed methods,
155 Annotation of BEC subpopulations).

156 Subpopulations zero, 5, 10 and 11 had similar expression levels and ridgeplot profiles
157 (histograms) to all other BEC subpopulations for the housekeeping gene beta-2
158 macroglobulin (B2M; Figure 2D; Additional file 2: Figure S12A). These subpopulations also
159 exhibited low, but similar in ridgeplot profiles to other BEC subpopulations, expression of
160 pan-EC genes (Figure 2C-D, Additional file 2: Figure S15A, B). Subpopulations zero and 5
161 contained a lower average number of genes per cell compared to other BEC subpopulations
162 (Additional file 2: Figure S12B) and did not express markers of 23 non-EC cell clusters of

163 human lung (Additional file 3: Table S1; Additional file 2: Figure S12C) or EC progenitors
164 (Additional file 2: Figure S12D).

165 Next, we used these novel identified signatures (Figure 4A) to test the hypothesis that BEC
166 subpopulation zero (the largest one in donor group in integrated dataset; Figure 3C) is
167 exclusively associated with ageing in the human lung. The comparison of scRNAseq datasets
168 of four ageing and three non-ageing/young human lungs against these signatures led to
169 annotation of BEC subpopulations in both age groups (Additional file 2: Figures S13, S14).
170 All signatures, except for subpopulations 1 and 2 (bronchial venules IPF Endo 1 and 2, which
171 are noticeably associated mainly with ageing IPF lung in cohorts 2 and 1 respectively; Figure
172 3C-D), were matching specific subpopulations in both age groups (as expected, since these
173 were donor lung samples, Additional file 2: Figure S14E). Cell number analysis revealed that
174 BEC subpopulation zero (identified as subpopulation A in ageing vs non-ageing/young lung
175 analysis), which has no obvious DEG, was present within ageing human lung only
176 (Additional file 2: Figures S13B-C, S14E), supporting our hypothesis and its annotation as an
177 ageing-related “de-differentiated” BEC (Figure 4A).

178 Finally, unsupervised hierarchical clustering of 12 subpopulations of ageing human lung
179 BEC revealed two distinct groups - “capillary/microvascular” and “macrovascular” (Figure
180 4B). In IPF, the relationships between subpopulations were altered, with “bronchial
181 venule/IPF Endo 1” and “intralobular venule” subpopulations “translocating” to “capillary/
182 microvascular” (Figure 4B).

183

184 **Cell Numbers for Bronchial Blood Vessel Endothelial Cell Subpopulations in Ageing** 185 **Distal Lung Depend on Fibrosis Degree and Bronchi Number in IPF**

186 To investigate the reason for differential cell numbers observed for two bronchial BEC
187 subpopulations (2 and 7; bronchial venule and capillary BEC respectively) in IPF (Figure 3C,
188 D), we focused on analysing scRNAseq data from the distal part of human ageing lungs

189 (cohort 1; four donors and four IPF patients; Figure 5 A, B). This analysis exposed
190 considerable variation in a percentage of subpopulation 2 cells between individual samples in
191 IPF (5.48 - 91.6 %), suggesting inter-lung sample heterogeneity. The comparison of
192 scRNAseq data with IPF lungs histology (based on haematoxylin and eosin staining) for each
193 individual case, which has been made available by the authors in the supplementary materials
194 section of the original study [27], revealed that the lowest percentage of subpopulation 2 cells
195 was detected in sample IPF04, where there was a noticeable lack of bronchial structures.
196 Based on these findings, we hypothesised that in IPF lung, significantly altered heterogeneity
197 (in terms of differential cell numbers) of ageing bronchial (and also possibly pulmonary and
198 lymphatic) endothelium reflects association with histological changes, i.e. tissue composition,
199 and, in particular, with the increase in percentage of (i) areas occupied by peri-bronchial
200 spaces undergoing fibrotic alterations and/or (ii) a number of bronchi, in particular, which
201 both underpin inter- and intra-lung heterogeneity in IPF.

202 To test this hypothesis, we analysed a distal lung surgical diagnostic lung biopsy from a
203 58-year-old male patient with IPF, confirmed by a histopathological pattern of UIP. First, we
204 identified 8 BEC subpopulations, including 2 and 7, by spatial position/localisation in ageing
205 human lung tissue of EC by immunostaining using two pan-endothelial (for various human
206 tissues, including lung) markers - platelet endothelial cell adhesion molecule (*PECAM-1*),
207 also known as cluster of differentiation 31 (CD31; [41]) and calcitonin receptor-like receptor
208 (CLR, encoded by *CALCRL* gene; [42-44]; see also Figure 1D) (Additional file 2: Figure
209 S15). Next, image analysis allowed quantification of IPF-associated changes in cell numbers
210 for subpopulations 2 and 7 (Figure 5C-I). The comparative analysis of low vs high degree
211 fibrotic areas within peri-bronchial regions in distal lung parenchyma identified no
212 differences in the number of CLR-positive nuclei in venules (vessel diameter $>7\mu\text{m}$) and a
213 significant decrease in capillaries (vessel diameter $<7\mu\text{m}$; Figure 5C-E; Additional file 2:
214 Figure S16), reflecting BEC from subpopulations 2 and 7 respectively, between groups.

215 Furthermore, comparative analysis of sections from two different areas of a distal lung
216 parenchyma from the same IPF patient revealed the association of percentage of CLR-
217 positive nuclei for both capillaries and venules with the number of bronchi (Figure 5F-I;
218 Additional file 2: Figure S17).

219 Altogether, these findings from immunohistochemistry corroborated the scRNAseq
220 analysis of IPF-associated changes in cell numbers of bronchial BEC subpopulations 2 and 7
221 in distal lung parenchyma in four IPF patients from cohort 1. Importantly, it revealed the
222 association of changes in cell numbers of ageing human BEC subpopulations 2 (venules) and
223 7 (capillaries) in peri-bronchial areas with the fibrosis degree and bronchi number.

224

225 **scRNAseq and Immunohistochemistry Reveal Fibrotic Alveolar Regions as Potential** 226 **Niches for Dedifferentiated Blood Vessel Endothelial Cell Subpopulations in IPF**

227 To investigate the possible location of BEC subpopulation zero in IPF, we focused on
228 analysing scRNAseq data from the distal part of human ageing lungs (cohort 1; four donors
229 and four IPF patients; Figure 6A). This exposed a noticeable variation in a percentage of cells
230 between individual samples in IPF (3.79 - 73 %; Figure 6A), suggesting their inter-lung
231 heterogeneity (similar to findings for BEC subpopulation 2; Figure 5B), and revealing a
232 negative correlation between subpopulations zero and two (Figure 6B). Interestingly, the
233 highest percentage of subpopulation zero cells was detected in the sample IPF04 (Figure 6C),
234 which according to histology of individual IPF lungs (based on haematoxylin and eosin
235 staining) for each individual case, which has been made available by the authors in the
236 supplementary materials section of the original study ([27]), was associated with the lack of
237 bronchial structures. Based on these findings and association of subpopulation zero with
238 pulmonary circulation (4A; based on negative score for bronchial circulation signature,
239 Figure 2F), we hypothesised that BEC subpopulation zero resides mainly in the alveolar

240 regions or “niches” of the distal part of human ageing lungs in IPF, where it is likely to derive
241 from BEC subpopulations 3, 4, 6 or 8 (Figures 2A, E, 3D and 4A).

242 To test this hypothesis, scRNAseq data analysis was focused on distal ageing human lung
243 samples (cohort 1), revealing that the increase in percentage of subpopulation zero cells in
244 IPF lungs was associated with a decreased in percentage of alveolar subpopulations 3, 4, 6 or
245 8 BEC, when they are analysed together, as a “single alveolar pool” in ageing human lung
246 (Figure 6D). Interestingly, subpopulation zero has expression profiles for housekeeping gene
247 B2M (Figure 1B, Additional file 2: Figure S12A) and pan-EC markers (*PECAMI/CD31* and
248 *CALCLR/CLR*) (Additional file 2: Figures S15A, B) comparable to all other ageing human
249 lung BEC subpopulations, whilst having a considerably larger proportion of cells with lower
250 expression of the latter two genes. Furthermore, quantitative analysis of *PECAMI* expression
251 in donor and fibrosis samples confirmed similarities in ridgeplot profiles between
252 subpopulation zero and alveolar BEC subpopulations 3, 4, 6 and 8 (in terms of presence of
253 both *PECAMI* positive and negative cells, as well as a trend for increased number of
254 *PECAMI* negative cells in fibrosis; Figure 6E, top and middle panels). Integrative analysis of
255 alveolar BEC subpopulations (3, 4, 6 and 8) and subpopulation zero taken together, as a
256 “single alveolar pool” in ageing human lung, revealed the trend for a reduction of *PECAMI*
257 expression (reflected by the decrease in percentage of positive cells) in fibrosis, also linked to
258 an increased variability between individual samples (Figure 6E, bottom panel).
259 Immunohistochemistry and image analysis of CD31 expression in distal alveoli in IPF lung
260 revealed a statistically significant decrease in proportion of CD31-positive nuclei and CD31
261 signal intensity in fibrotic compared to non-fibrotic alveoli (Figure 6 F-H; Additional file 2:
262 Figure S18). Combining analysis of *PECAMI/CD31* expression by scRNAseq and
263 immunohistochemistry revealed similar decreases in expression (compare last graphs in
264 Figures 6E and H), thus supporting our hypothesis that BEC subpopulation zero resides
265 mainly in the alveolar regions/niches of the distal part of human ageing lungs in IPF.

266

267 **Expression of Genes Linked to Disease-Specific Signalling Pathways and Endothelial**
268 **Cell Processes is Altered in Ageing Lung Blood Vessel Endothelium in IPF**

269 Comparison of gene expression between donor and IPF lungs led to identification of 3596
270 significantly regulated (1600 down- and 1996 up-) DEG across 12 BEC subpopulations
271 (Figures 7A-B, Additional file 2: Figure S19A; Additional file 3: Table S7). There were
272 significant associations with specific signalling pathways in 7 (two bronchial and 5
273 pulmonary, including two “de-differentiated”) from 12 subpopulations (Figure 7C). DEG in
274 subpopulations zero, 8 and 11 were directly linked to IPF-associated pathways, and in four
275 others (1, 3, 5 and 11) - with fibrotic or inflammatory pathways (Figures 7C, Additional file
276 2: Figure S19B). Next, the utilisation of published gene set enrichment analysis (GSEA)
277 libraries for the assessment of expression of marker genes which are associated with ten EC-
278 relevant processes revealed positive module scores in 5-12 of the BEC subpopulations for
279 individual processes on average (Additional file 2: Figure S20) and significant changes in
280 several (3 bronchial and 6 pulmonary, including two “de-differentiated”) BEC
281 subpopulations in IPF (Figure 7D-E). This reflected subpopulation-specific pattern of
282 endothelium response to the fibrotic lung environment in all processes, ranging from two (for
283 senescence) to 8 (for vasodilation) subpopulations amongst 9 analysed (Figures 7E).

284

285 **Integrated Single Cell Map and Immunohistochemistry of Ageing Human Lung**
286 **Lymphatic Endothelium Reveal Its Heterogeneity and Contribution in IPF**

287 Unsupervised clustering of subtracted ageing human lung LEC alone in integrated dataset
288 (689 cells) identified two main populations consisting of five distinct, and to our knowledge
289 previously uncharacterised, subpopulations in total (Figures 1A, 8A), as based on their DEG
290 patterns (top 10 DEG for each, 50 in total, with 20 not associated with LEC formerly [22, 26]
291 (Figures 8B-D; Additional file 2: Figure S21, 22F) and cell cycle analysis (Additional file 2:

292 Figure S23). All signatures were specific in recognising individual LEC subpopulations
293 (Additional file 2: Figure S21A-B). Intriguingly, ageing human lung LEC subpopulations 1
294 and 2 were present only in cohort 1 and subpopulations zero, three and 4 – exclusively in
295 cohort 2 (Additional file 2: Figure S24). Quantification of cell numbers revealed a trend for a
296 decrease (for subpopulations 1 and 2) but overall a lack of non-significant changes for all
297 subpopulations between donor and IPF lungs in integrated (Additional file 2: Figure S24A-B;
298 Additional file 3: Table S9) or percentage contribution when split by cohort (Additional file
299 2: Figure 24C-E; Additional file 3: Table S9) datasets, in contrast to cell number data on BEC
300 (Figure 3C, D). Altogether, our findings formed the foundation for detailed transcriptional
301 characterisation of five distinct (informed by DEG, our transcriptional signatures, sample
302 collection site and cell cycle information) LEC subpopulations in ageing human lung (Figure
303 8D; in-depth description is provided in Additional file 1: Detailed methods, Annotation of
304 LEC Subpopulations).

305 To investigate the reason for non-differential cell numbers observed for ageing human
306 LEC in IPF (Additional file 2: Figure S24), compared to differential cell numbers observed
307 for two bronchial BEC subpopulations (2 and 7), we focused scRNAseq data analysis on two
308 LEC subpopulations (1 and 2) detected in the distal part of human ageing lungs from four
309 donors and four IPF patients (cohort 1; Figure 8E). This exposed very small variation in a
310 percentage of subpopulation 2 (PDPN-positive) cells between individual samples in IPF (0.71
311 - 5.20%; Figure 8E), contrasting findings for BEC subpopulations zero, two and 7 (Figures
312 5B and 6A, C). Based on this observation and on histology from 4 previous reports, jointly
313 covering 5 different structures in ageing lung in donors or IPF patients [9, 11, 26, 46], we
314 hypothesised that PDPN-positive LEC are distributed uniformly in all tissue regions
315 (bronchial and alveolar) within ageing human distal lung parenchyma in IPF.

316 For testing this hypothesis, we immunostained human IPF lung tissue using anti-PDPN
317 antibody D2-40 (Figure 8 F, G). The quantification analysis of immunostaining in this distal

318 lung parenchyma sample uncovered signs of developing fibrosis and substantial intra-lung
319 heterogeneity throughout the section areas/regions and revealed the distribution of PDPN-
320 positive vessels (Additional file 2: Figure S25). Interestingly, the comparison to inter-lung
321 heterogeneity, which was detected across four samples within cohort 1 (as demonstrated by
322 histological analysis using haematoxylin and eosin staining; [27]) and cohort 2 (as
323 demonstrated by immunohistochemistry images presented by the authors; [25]) detected the
324 presence of all identifiable structures from both cohorts (non-fibrotic and fibrotic alveolae,
325 bronchiole and honeycomb cyst in cohort 1; and large artery and veins, bronchiole and pleura
326 in cohort 2) within the surgical distal lung biopsy. It also revealed uniform distribution of
327 PDPN-positive LEC nuclei in all detected tissue regions (bronchial, alveolar and pleural)
328 within ageing human distal lung parenchyma and honeycomb cyst regions (Figure 8 F-G;
329 Additional file 2: Figure S25). Together with finding from scRNAseq data analysis, which
330 showed that in ageing human lung PDPN-positive LEC subpopulation 2 was present only in
331 cohort 1, whilst PDPN-positive LEC subpopulations zero and 4 - exclusively in cohort 2
332 (Figure 8C), these data suggest that our immunostaining detected all three subpopulations of
333 PDPN-positive LEC subpopulations (zero, two and 4) in ageing human lung in IPF within
334 our single diagnostic biopsy (Figure 8 F-G).

335 Next, high content image quantification of cell numbers/percentage of cells revealed
336 uniform percentages of PDPN-positive LEC across analysed bronchial, alveolar and
337 subpleural regions, including both fibrotic and non-fibrotic regions (ranging from 4.5% to
338 20.9%; Figure 8 H; Additional file 2; Figure S25). These findings support scRNAseq analysis
339 data, which revealed lack of significant differences for these subpopulations in IPF lungs in
340 the integrated dataset (Additional file 2: Figure S24A-B; Additional file 3: Table S9), thus
341 supporting our hypothesis.

342 Finally, gene expression comparison between donor and IPF lungs led to identification of
343 101 significantly up-regulated DEG across 5 LEC subpopulations (Figures 8I), compared to

344 3596 DEG for ageing human lung BEC (Figure 7B) and significant linkage to IPF-associated
345 pathways in subpopulations zero and one (Additional file 2: Figure S26). Finally, the
346 utilisation of GSEA libraries identified significant alterations in ageing human lung LEC, in
347 IPF (Figure 8J; Additional file 2: Figure S26 C-L).

348

349 **Discussion**

350 The role of the lung circulatory system, including both blood and lymphatic vessel networks,
351 has been implicated in IPF pathophysiology, but subpopulations of endothelium in ageing
352 human lung and their disease-specific properties remained insufficiently characterized.
353 Previous studies aimed at generating cellular atlases have predominantly used diverse
354 datasets from healthy donors and patients with different diseases covering a wide range of
355 ages, ethnicities and other characteristics [22, 25-27, 30, 32]. This complicated the
356 deconvolution of a highly heterogeneous population of specialized cells in human lung and
357 detection of changes triggered by the ageing process itself, as well as additional alterations
358 caused by individual age-associated diseases. We generated a first integrated (multi-cohort)
359 map of individual cell populations in ageing human lung in IPF and identified the
360 contribution of blood and lymphatic vessels endothelium. This resource can be used as a
361 foundation for identifying and studying ageing endothelium in other age-associated chronic
362 lung diseases.

363 The identification and annotation of 17 subpopulations of endothelium (12 BEC and 5
364 LEC), with distinct molecular signatures and percentage contribution in ageing human lung
365 in donors and IPF patients, is of particular significance. Integrated single-cell maps of the
366 ageing human lung endothelium advanced resolution of BEC and LEC populations,
367 increasing the number of formerly identified in ageing human lung EC subtypes [21, 22]
368 from 9 to 17 and revealing previously underappreciated extent of their diversity and
369 heterogeneity, especially in distal lung. Apart from confirming the presence of three

370 bronchial and 8 pulmonary, as well as one “intermediary” (inflammatory), subpopulations,
371 our integrative analysis detected four to our knowledge previously uncharacterised
372 subpopulations of BEC in ageing human lung, when compared to previous scRNAseq reports
373 [21, 22, 24]. Spatial validation based on immunohistochemistry using pan-EC markers
374 confirmed the presence of 8 of these 12 BEC subpopulations in the distal ageing human lung.
375 Our study also revealed the existence of 5 subpopulations of ageing LEC by transcriptional
376 analysis. DEG signatures for 17 subpopulations of ageing human lung endothelium contain
377 59 novel subpopulation-specific candidate genes (39 for BEC, 20 for LEC). The pathway
378 analysis of these DEG provides a springboard for exploring their roles and potential as
379 biomarkers for diagnostics and/or prognostics in IPF.

380 Our study identified two BEC subpopulations (10 and 11, “Pneumocyte marker (low)
381 expressing” and “Immune marker (low) expressing” respectively) in both the young and the
382 ageing human lung. These subpopulations have been previously characterised in murine and
383 porcine models [47-49], but to our knowledge have not been yet identified in the human lung.
384 The pneumocyte marker (low) expressing subpopulation had been found in the context of
385 pulmonary hypertension or obesity in mice [47, 48] and surfactant proteins have been
386 detected in the circulation in IPF [50, 51]. The immune marker (low) expressing
387 subpopulation had been found in porcine vasculature via generation of a multiple-organ
388 single-cell transcriptomic map [49]. In human lung, these cells express markers of EC
389 progenitors, including hematopoietic cells and hemogenic endothelium [52, 53]. These
390 findings and abundance of both BEC subpopulations 10 and 11 in distal human lung warrant
391 further studies to dissect their functions/roles in physiological conditions and chronic lung
392 diseases.

393 To our knowledge, the identification of ageing human lung BEC subpopulations belonging
394 to bronchial or pulmonary circulation or specific lymphatic networks [19, 20], including two
395 subpopulations of “de-differentiated” cells (zero and 5), has not been conducted before our

396 study. These “de-differentiated” BEC subpopulations were present in all nine analysed ageing
397 human lungs from 49-72 years old subjects and belonged exclusively to pulmonary
398 circulation. Findings from our scRNAseq analysis in IPF are in accordance with reports
399 about the plasticity of endothelium and loss of EC identity, frequently associated with Endo-
400 MT in vascular disorders [7, 54-56]. In our study, decreases in EC differentiation scores in
401 three BEC subpopulations (zero, 4 and 7) and one LEC subpopulation (zero) in IPF co-
402 occurred with increases in mesenchymal score. These findings suggest that Endo-MT, which
403 has been previously proposed in IPF [56, 57], is also one of the subpopulation-specific
404 features of the ageing human lung endothelium in this disease.

405 Lower average number of genes per cell associated with ageing human lung BEC de-
406 differentiation in subpopulations zero and 5 has been also observed in few subpopulations of
407 other cell types within ageing human lung in our study, concordant to findings for individual
408 cell subpopulations identified in scRNAseq studies of ageing tissues from other organs [58,
409 59]. Importantly, subpopulations zero and 5 have comparable levels of the housekeeping gene
410 *B2M* and pan-EC marker expression profiles (ridgeplots) to other ageing human lung BEC
411 subpopulations, whilst having a considerably larger proportion of cells with lower expression
412 of *PECAMI* and *CALCRL*. Together with distinct clustering of BEC population, including
413 these two subpopulations, away from the rest of cell populations within the integrated single
414 cell map of ageing human lungs (Figure 1B), these data support the identity of
415 subpopulations zero and 5 as EC. The age-associated de-differentiation of human lung
416 endothelium subpopulations, especially from alveolar regions (BEC sub-populations 3, 4, 6
417 and 8), is the most likely explanation for their “contribution” to subpopulation zero, which
418 contained ~30% of BEC in ageing human lungs. Together with pseudotime analysis data
419 demonstrating that subcluster zero potentially act as a convergence “hub” for 7
420 subpopulations of ageing BEC, these findings could serve as an explanation for

421 immunohistochemistry-based findings in our study and other reports using pan-EC markers
422 and suggesting a loss of vasculature in IPF lung [10, 60].

423 Cell cycle analysis revealed that the majority (over 50%) of the cells in subpopulations
424 zero, 4-7 and 9 in ageing human lung were in S phase. Cell cycle arrest and increase in S
425 phase proportion have been linked to cell senescence in studies using *in vivo* or *in vitro*
426 models, including murine lung EC [59, 61]. All nine analysed ageing human lung BEC
427 subpopulations had positive senescence scores, which increased only in two pulmonary
428 subpopulations, “de-differentiated capillary” and “aerocyte”, in IPF. Senescence has been
429 classified as a hallmark of ageing [4], but remains challenging to analyse in human tissues
430 and EC within any organ. To date, the presence of senescent endothelium has been associated
431 with hypertension and increased cardiovascular disease risk, but not chronic lung diseases or
432 lung circulatory system pathology, in elderly subjects [62-64]. In our study, we report the
433 presence and location of senescent EC in ageing blood vessels within distal lung parenchyma
434 diagnostic biopsy of IPF, warranting further investigation.

435 The age-associated decline in properties of highly specialized EC subpopulations in
436 human lung (de-differentiation due to Endo MT, global reduction in gene expression, and
437 senescence) is likely to contribute to alterations of function of individual vessel sub-types
438 comprising respective blood and lymphatic systems. Further exploration is needed into
439 dissecting whether further de-differentiation or senescence [65] in individual subpopulations
440 of IPF endothelium contribute to disease pathophysiology and/or progression and may
441 present further avenues for therapy using drugs targeting these pathways in elderly.
442 Furthermore, although rare, IPF can occur in younger adult populations (11.3 per 100,000
443 individuals; [66]), with a significant paucity of studies investigating the mechanisms of lung
444 fibrosis pathogenesis. The contribution of revealed in our study ageing human lung BEC-
445 related processes, and “de-differentiation” in particular, to IPF pathophysiology and
446 susceptibility in young population requires further investigation.

447 Disease-specific heterogeneity of ageing human lung endothelium in IPF patients
448 involves changes in the percentage contribution and transcriptional profiles of individual EC
449 subpopulations. In IPF, observed significant increase in cell numbers in two (bronchial
450 venules IPF Endo 1 and 2) and decrease in one (bronchial capillary) BEC subpopulations is
451 associated with fibrosis, bronchi number and tissue sample location (distal parenchyma or
452 other regions within lung), but accompanied by the lack of significant changes in lymphatic
453 endothelium. These findings for ageing BEC are in accordance with IPF-associated changes
454 for “VE peribronchial” subpopulation, which was identified by conducting analysis of age-
455 unmatched lung tissue samples [25]. This subpopulation shares a degree of similarity with
456 two subpopulations of ageing human lung BEC identified in our study - IPF Endo 1 and 2,
457 which are transcriptionally distinct and derived from two independent cohorts (Figures 2F,
458 3D), with only one being from the same scRNAseq dataset as “VE peribronchial”
459 subpopulation. Observed in our study decrease in percentage contribution of total LEC
460 (Figure 1G) or LEC sub-population 2 in cohort 1 (distal lung samples) in IPF was non-
461 significant, but concurs with decline observed by others in lymphatic vessel density in distal
462 lung parenchyma in IPF [9]. These findings warrant further investigation of the specific
463 bronchial BEC and LEC subpopulations as potential cellular targets for therapeutic
464 management in IPF.

465 Changes in transcriptional profiles of individual subpopulations of ageing human lung EC
466 related to key EC-relevant processes suggest their subpopulation-specific functional
467 responses within the fibrotic lung microenvironment and roles in IPF pathophysiology.
468 Alterations in three pulmonary BEC and one LEC subpopulation in IPF lung included DEG
469 which significantly mapped to IPF pathways. This finding suggests previously unrecognized
470 direct involvement of “de-differentiated”, “aerocyte” and “immune marker (low) expressing”
471 BEC (subpopulations zero, 8 and 11 respectively) and LEC subpopulation 1 from ageing
472 human lung in IPF and their potential utility as targets for therapy. Moreover, the association

473 of DEG in one bronchial and three pulmonary BEC subpopulations with fibrotic or
474 inflammatory pathways implies their active roles in IPF progression. Finally, the
475 translocation of IPF Endo 1 subpopulation from the macrovascular to the
476 capillary/microvascular group in IPF suggests a disease-specific shift in its transcriptional
477 phenotype to a capillary/microvascular-like endothelium, which co-occurs with changes to its
478 vascular tone and permeability.

479 Previous studies of lung vasculature in IPF suggest a contribution of increased
480 permeability [15, 16], aberrant angiogenesis [67] and endothelial dysfunction [17] in blood
481 vessels to the fibrotic lung microenvironment and disease progression. Our data show that
482 eight BEC and two LEC subpopulations exhibit decreases in vasodilation scores, with five of
483 these subpopulations (including two bronchial and two pulmonary “de-differentiated” BEC
484 and LEC subpopulation one) also showing reduction in permeability scores in IPF. Two
485 common co-morbidities in IPF are cardiovascular disease and pulmonary hypertension [68,
486 69], suggesting that systemic as well as lung-specific endothelial dysfunction could be
487 contributing to IPF. Secondary endpoints in a recent clinical trial of the prostacyclin analogue
488 treprostinil via non-systemic delivery (inhalation) to treat IPF patients with pulmonary
489 hypertension, included improved lung function and a decrease in fibrosis progression events
490 compared to placebo [70, 71]. These data are intriguing in the context of our findings
491 indicating that pulmonary “de-differentiated” endothelium (subpopulations zero and 5) and
492 the BEC from the “singular alveolar pool” (3, 4, 6 and 8) in IPF could be primary cellular
493 targets for inhalation-based therapies affecting expression of genes involved in regulation of
494 EC identity and vascular tone. Avenues for targeting these and other BEC or LEC
495 subpopulations, which show changes in vasodilation and permeability scores in IPF, for
496 therapy should be therefore explored/investigated.

497 To our knowledge, a limited number of studies characterizing individual lymphatic
498 system networks (and vessel sub-types or LEC composing them) in physiologically ageing or

499 ageing-associated IPF lungs have been conducted to date with main focus on intralobular and
500 sub-pleural lymphatics [9, 11, 20, 26, 46]. Our study revealed 5 distinct sub-populations
501 (based on 20 novel DEG and including three PDPN-positive subpopulations) of LEC, all with
502 statistically unchanged cell numbers and modest changes in gene expression in IPF (101 vs
503 3596 DEG, when compared to BEC). The study also uncovered uniform distribution of
504 PDPN-positive vessels in all tissue regions (bronchial, alveolar and pleural) within ageing
505 human distal lung parenchyma detected using a single diagnostic biopsy of IPF. These
506 findings bridge and substantially expands knowledge available from previous studies [9, 11,
507 26, 39, 40, 45, 46] to include honeycomb cysts. At the same time, this warrants further
508 annotation and spatial validation of these subpopulation to facilitate dissection of their roles
509 in pathophysiology of IPF and other chronic lung diseases.

510 IPF-associated changes in transcriptional profiles of LEC suggest subpopulation-specific
511 pattern of responses to the fibrotic lung environment (with only 101 DEG in LEC
512 subpopulations compared to 3596 identified for BEC), affecting EC-relevant processes
513 predominantly in LEC from sub-populations zero and two. Transcriptional changes in LEC
514 from ageing lung are likely to account for the alterations in their properties and reported
515 “disappearance” of subpleural and interlobular lymphatics in IPF by others [9]. Furthermore,
516 the network of subpleural lymphatic capillaries drains lymph from the surface of the lung
517 [20] and presents potential route for drug delivery to distal lung tissue affected by fibrotic
518 changes in IPF [72]. Lymphatics have been considered an attractive option for targeted
519 therapy in cancer and should be also exploited for the management of IPF and other chronic
520 lung diseases [73]. Therefore, further investigations of the roles of ageing human LEC in the
521 fibrotic lung environment is warranted.

522 Current therapy for IPF patients aims to slow disease progression and maintain lung
523 function [74, 75]. Two medications, nintedanib and pirfenidone, have been approved for the
524 treatment of IPF on the basis of reductions in the rate of physiologic decline, but the disease

525 still progresses in treated patients and there remains no cure [76]. Promising clinical trials
526 such as the recent trial of treprostinil [70, 71] continue to improve the outlook for future
527 therapy. Understanding the properties of individual circulation networks, blood and
528 lymphatic EC subpopulations and their altered functions within pre-fibrotic and fibrotic
529 microenvironments in IPF lung presents possible avenues for management (halting or
530 reversing progression) of this debilitating and life-threatening disease. IPF endothelium and
531 its individual subpopulations present potential cellular targets for therapy repurposing
532 appropriate anti-fibrotic, -inflammatory or -senescence drugs in IPF, including the
533 possibilities for personalised medicine.

534

535 **Conclusions**

536 In summary, our study discovered the phenomenon of the distinct “IPF endothelium”
537 phenotype/state in ageing human lung, which contributes to UIP pattern in IPF. We propose
538 that disease-specific heterogeneity of ageing human lung endothelium (from blood and
539 lymphatic vessels) should be considered as a hallmark of IPF. In the future, the exploitation
540 of the knowledge about EC heterogeneity, including properties and functions of individual
541 EC subpopulations, in ageing human lung has the potential in IPF to protect lung function,
542 improving patients’ quality of life and survival. Our molecular findings should help with
543 building a conceptual framework for appreciating the endothelium in ageing human lung as a
544 significant contributor and a probable target for biomarker development and/or therapy in
545 IPF, other chronic lung diseases and diseases associated with fibrosis in other organs,
546 including lymphoedema and cancer.

547

548 **Methods**

549 To characterise ageing human lung endothelium in IPF and to account for its intra- and inter-
550 lung heterogeneity (within and between individuals; [29]), we conducted the comparative

551 analysis of lung tissues from elderly IPF patients and healthy donors (49-72 years old for
552 both groups) by integrating scRNAseq datasets from two independent cohorts, each
553 composed of age-matched healthy and IPF lung samples [25, 27]. We generated integrated
554 single-cell maps of ageing human lung endothelium, identified EC subpopulations and
555 characterised their transcriptional profiles, differences in percentage contribution and gene
556 expression signatures, and also conducted spatial analysis of findings by performing
557 immunohistochemistry and high content microscopy using distal lung diagnostic biopsy of
558 IPF (with confirmed histopathological pattern of usual interstitial pneumonia). Full details of
559 the methods are provided in Additional file 1: Detailed methods.

560

561 **Declarations**

562

563 *Ethics approval and consent to participate.* This study utilised publicly available data.
564 Detailed information can be found in the original articles [25; 27]. Analysis of surplus human
565 lung biopsy tissue by immunohistochemistry was approved by the Hull and East Riding
566 Research Ethics Committee (reference 08/H1304/54).

567

568 *Consent for publication.* Not applicable.

569

570 *Availability of data and materials.* The datasets analysed during the current study are
571 available in gene expression omnibus (GEO). Data from cohort 1 [27] is available at
572 GSE122960_RAW: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122960> and in
573 cohort 2 [25] - from GSE136831_RAW:
574 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136831>.

575

576 *Competing interests.* The authors declare that they have no competing interests.

577

578 *Funding.* Kate Garthwaite Pulmonary Fibrosis Research Fund; University of Hull Endothelial
579 Cell Research Fund; University of Hull PhD Scholarships Fund for “Health Global Data
580 Pipeline (Health*GDP) for Biomedical Research and Clinical Applications” cluster; The
581 Anatomical Society.

582

583 *Author contributions.* ECF, SPH and LLN contributed to study conception and design. ECF,
584 AAM and LLN performed bioinformatic analysis. ECF and LLN performed
585 immunohistochemistry staining and image analysis. ECF and LLN analysed and interpreted
586 data. SPH and LLN supervised study execution. ECF and LLN drafted the manuscript. All
587 authors reviewed the manuscript.

588

589 *Acknowledgements.* We thank all transplant donors and IPF patients who participated in the
590 several studies analysed in this manuscript and the authors who made scRNAseq datasets
591 publicly available. Mr Collins and Viper HPC Team, Drs Peter O’Toole, Joanne Marrison
592 (both from The University of York Biotechnology Facility Team), Professors Adrian Harris,
593 Anthony Maraveyas, Tatsuo Shimosawa and John Greenman, Drs Sarah De Val, Stephen
594 Henderson, Camille Ettelaie, Markus Queisser, Veronica Carroll, Vicky Green, Mr Matthew
595 Morfitt, Mr Dimitrios Manolis, Mrs Shirin Hasan and Mrs Nicola Briggs for their support.

596 **References**

- 597 1. Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: A
598 review. *Curr Pulmonol Rep* 2018; 7: 118-125.
- 599 2. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi
600 H, Wells AU. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers* 2017; 3: 17074.
- 601 3. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M.
602 Global incidence and prevalence of idiopathic pulmonary fibrosis. *Respiratory*
603 *research* 2021; 22: 1-10.
- 604 4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of ageing.
605 *Cell* 2013; 153: 1194-1217.
- 606 5. Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with
607 idiopathic pulmonary fibrosis in the UK. *Advances in therapy* 2018; 35: 724-736.
- 608 6. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. *Annu*
609 *Rev Pathol* 2014; 9: 157-179.
- 610 7. Gaikwad AV, Lu W, Dey S, Bhattarai P, Chia C, Larby J, Haug G, Myers S, Jaffar J,
611 Westall G, Singhera GK, Hackett TL, Markos J, Eapen MS, Sohal SS. Vascular
612 remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on
613 lung physiology: potential role of endothelial-to-mesenchymal transition. *ERJ Open*
614 *Res* 2022; 8.
- 615 8. Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic System in
616 Cardiovascular Medicine. *Circ Res* 2016; 118: 515-530.
- 617 9. Ebina M, Shibata N, Ohta H, Hisata S, Tamada T, Ono M, Okaya K, Kondo T, Nukiwa T.
618 The disappearance of subpleural and interlobular lymphatics in idiopathic pulmonary
619 fibrosis. *Lymphatic research and biology* 2010; 8: 199-207.
- 620 10. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T,
621 Nukiwa T. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic

- 622 pulmonary fibrosis. *American journal of respiratory and critical care medicine* 2004;
623 169: 1203-1208.
- 624 11. El-Chemaly S, Malide D, Zudaire E, Ikeda Y, Weinberg BA, Pacheco-Rodriguez G,
625 Rosas IO, Aparicio M, Ren P, MacDonald SD, Wu HP, Nathan SD, Cuttitta F,
626 McCoy JP, Gochuico BR, Moss J. Abnormal lymphangiogenesis in idiopathic
627 pulmonary fibrosis with insights into cellular and molecular mechanisms. *Proc Natl*
628 *Acad Sci U S A* 2009; 106: 3958-3963.
- 629 12. Gaje PN, Stoia-Djeska I, Cimpean AM, Ceausu RA, Tudorache V, Raica M.
630 Lymphangiogenesis as a Prerequisite in the Pathogenesis of Lung Fibrosis. *In vivo*
631 2014; 28: 367-373.
- 632 13. Glasgow CG, El-Chemaly S, Moss J. Lymphatics in lymphangiomyomatosis and
633 idiopathic pulmonary fibrosis. *European Respiratory Review* 2012; 21: 196-206.
- 634 14. Lara AR, Cosgrove GP, Janssen WJ, Huie TJ, Burnham EL, Heinz DE, Curran-Everett D,
635 Sahin H, Schwarz MI, Cool CD. Increased lymphatic vessel length is associated with
636 the fibroblast reticulum and disease severity in usual interstitial pneumonia and
637 nonspecific interstitial pneumonia. *Chest* 2012; 142: 1569-1576.
- 638 15. Montesi SB, Rao R, Liang LL, Goulart HE, Sharma A, Digumarthy SR, Shea BS,
639 Seethamraju RT, Caravan P, Tager AM. Gadofosveset-enhanced lung magnetic
640 resonance imaging to detect ongoing vascular leak in pulmonary fibrosis. *European*
641 *Respiratory Journal* 2018; 51.
- 642 16. Montesi SB, Zhou IY, Liang LL, Digumarthy SR, Mercaldo S, Mercaldo N, Seethamraju
643 RT, Rosen BR, Caravan P. Dynamic contrast-enhanced magnetic resonance imaging
644 of the lung reveals important pathobiology in idiopathic pulmonary fibrosis. *ERJ open*
645 *research* 2021; 7; 00907-2020
- 646 17. Probst CK, Montesi SB, Medoff BD, Shea BS, Knipe RS. Vascular permeability in the
647 fibrotic lung. *European Respiratory Journal* 2020; 56; 1900100

- 648 18. Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary
649 fibrosis: pathogenesis and management. *Respiratory research* 2018; 19: 1-18.
- 650 19. Sharara RS, Hattab Y, Patel K, DiSilvio B, Singh AC, Malik K. Introduction to the
651 anatomy and physiology of pulmonary circulation. *Critical Care Nursing Quarterly*
652 2017; 40: 181-190.
- 653 20. Stump B, Cui Y, Kidambi P, Lamattina AM, El-Chemaly S. Lymphatic Changes in
654 Respiratory Diseases: More than Just Remodeling of the Lung? *Am J Respir Cell Mol*
655 *Biol* 2017; 57: 272-279.
- 656 21. Sauler M, McDonough JE, Adams TS, Kothapalli N, Barnthaler T, Werder RB, Schupp
657 JC, Nouws J, Robertson MJ, Coarfa C. Characterization of the COPD alveolar niche
658 using single-cell RNA sequencing. *Nature Communications* 2022; 13: 1-17.
- 659 22. Travaglini KJ, Nabhan AN, Penland L, Sinha R, Gillich A, Sit RV, Chang S, Conley SD,
660 Mori Y, Seita J, Berry GJ, Shrager JB, Metzger RJ, Kuo CS, Neff N, Weissman IL,
661 Quake SR, Krasnow MA. A molecular cell atlas of the human lung from single-cell
662 RNA sequencing. *Nature* 2020; 587: 619-625.
- 663 23. Stuart T, Satija R. Integrative single-cell analysis. *Nat Rev Genet* 2019; 20: 257-272.
- 664 24. Neumark N, Cosme Jr C, Rose K-A, Kaminski N. The idiopathic pulmonary fibrosis cell
665 atlas. American Physiological Society Bethesda, MD; 2020. p. L887-L892.
- 666 25. Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, Chu SG, Raby BA,
667 DeJuliis G, Januszyk M. Single-cell RNA-seq reveals ectopic and aberrant lung-
668 resident cell populations in idiopathic pulmonary fibrosis. *Science advances* 2020; 6:
669 eaba1983.
- 670 26. Schupp JC, Adams TS, Cosme Jr C, Raredon MSB, Yuan Y, Omote N, Poli S, Chioccioli
671 M, Rose K-A, Manning EP. Integrated single-cell atlas of endothelial cells of the
672 human lung. *Circulation* 2021; 144: 286-302.

- 673 27. Reyfman PA, Walter JM, Joshi N, Anekalla KR, McQuattie-Pimentel AC, Chiu S,
674 Fernandez R, Akbarpour M, Chen C-I, Ren Z. Single-cell transcriptomic analysis of
675 human lung provides insights into the pathobiology of pulmonary fibrosis. *American*
676 *journal of respiratory and critical care medicine* 2019; 199: 1517-1536.
- 677 28. Morse C, Tabib T, Sembrat J, Buschur KL, Bittar HT, Valenzi E, Jiang Y, Kass DJ,
678 Gibson K, Chen W. Proliferating SPP1/MERTK-expressing macrophages in
679 idiopathic pulmonary fibrosis. *European Respiratory Journal* 2019; 54(2):1802441
- 680 29. He D, Wang D, Lu P, Yang N, Xue Z, Zhu X, Zhang P, Fan G. Single-cell RNA
681 sequencing reveals heterogeneous tumor and immune cell populations in early-stage
682 lung adenocarcinomas harboring EGFR mutations. *Oncogene* 2021; 40: 355-368.
- 683 30. Habermann AC, Gutierrez AJ, Bui LT, Yahn SL, Winters NI, Calvi CL, Peter L, Chung
684 M-I, Taylor CJ, Jetter C. Single-cell RNA sequencing reveals profibrotic roles of
685 distinct epithelial and mesenchymal lineages in pulmonary fibrosis. *Science advances*
686 2020; 6: eaba1972.
- 687 31. Luecken MD, Zaragosi LE, Madisson E, Sikkema L, Firsova AB, De Domenico E, et al.
688 The discovAIR project: a roadmap towards the Human Lung Cell Atlas. *Eur Respir J.*
689 2022;60(2). 2102057
- 690 32. Vieira Braga FA, Kar G, Berg M, Carpaij OA, Polanski K, Simon LM, Brouwer S,
691 Gomes T, Hesse L, Jiang J, Fasouli ES, Efremova M, Vento-Tormo R, Talavera-
692 López C, Jonker MR, Affleck K, Palit S, Strzelecka PM, Firth HV, Mahbubani KT,
693 Cvejic A, Meyer KB, Saeb-Parsy K, Luinge M, Brandsma CA, Timens W, Angelidis
694 I, Strunz M, Koppelman GH, van Oosterhout AJ, Schiller HB, Theis FJ, van den
695 Berge M, Nawijn MC, Teichmann SA. A cellular census of human lungs identifies
696 novel cell states in health and in asthma. *Nat Med* 2019; 25: 1153-1163.

- 697 33. Gillich A, Zhang F, Farmer CG, Travaglini KJ, Tan SY, Gu M, Zhou B, Feinstein JA,
698 Krasnow MA, Metzger RJ. Capillary cell-type specialization in the alveolus. *Nature*
699 2020; 586: 785-789.
- 700 34. Herwig N, Belter B, Pietzsch J. Extracellular S100A4 affects endothelial cell integrity
701 and stimulates transmigration of A375 melanoma cells. *Biochemical and Biophysical*
702 *Research Communications* 2016; 477: 963-969.
- 703 35. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch
704 signaling pathway. *J Cell Physiol* 2003; 194: 237-255.
- 705 36. Nukala SB, Tura-Ceide O, Aldini G, Smolders V, Blanco I, Peinado VI, Castellà M,
706 Barberà JA, Altomare A, Baron G, Carini M, Cascante M, D'Amato A. Protein
707 network analyses of pulmonary endothelial cells in chronic thromboembolic
708 pulmonary hypertension. *Sci Rep* 2021; 11: 5583.
- 709 37. Ochiya T, Takenaga K, Endo H. Silencing of S100A4, a metastasis-associated protein, in
710 endothelial cells inhibits tumor angiogenesis and growth. *Angiogenesis* 2014; 17: 17-
711 26.
- 712 38. Vanlandewijck M, He L, Mäe MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier
713 T, Laviña B, Gouveia L, Sun Y, Raschperger E, Räsänen M, Zarb Y, Mochizuki N,
714 Keller A, Lendahl U, Betsholtz C. A molecular atlas of cell types and zonation in the
715 brain vasculature. *Nature* 2018; 554: 475-480.
- 716 39. Sibling E, He Y, Ducoli L, Keller N, Fujimoto N, Dieterich LC, Detmar M. Single-cell
717 transcriptional heterogeneity of lymphatic endothelial cells in normal and inflamed
718 murine lymph nodes. *Cells* 2021; 10: 1371.
- 719 40. Takeda A, Hollmén M, Dermadi D, Pan J, Brulois KF, Kaukonen R, Lönnberg T,
720 Boström P, Koskivuo I, Irjala H, Miyasaka M, Salmi M, Butcher EC, Jalkanen S.
721 Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell

- 722 Heterogeneity and Mechanisms of Homing for Neutrophils. *Immunity* 2019; 51: 561-
723 572.e565.
- 724 41. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical Expression of
725 Endothelial Markers CD31, CD34, von Willebrand Factor, and Fli-1 in Normal
726 Human Tissues. *Journal of Histochemistry & Cytochemistry*. 2006;54(4):385-395
- 727 42. Nikitenko LL, Smith DM, Bicknell R, Rees MC. Transcriptional regulation of the CRLR
728 gene in human microvascular endothelial cells by hypoxia. *FASEB J*. 2003
729 Aug;17(11):1499-501.
- 730 43. Nikitenko LL, Blucher N, Fox SB, Bicknell R, Smith DM, Rees MC. Adrenomedullin
731 and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial
732 cells and induce its desensitisation by different mechanisms. *J Cell Sci*. 2006;119(Pt
733 5):910-22.
- 734 44. Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S,
735 Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB. The G-protein-coupled
736 receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell
737 renal cell carcinoma and associated with poor prognosis. *Clin Cancer Res*.
738 2013;19(20):5740-8.
- 739 45. Xiang M, Grosso RA, Takeda A, Pan J, Bekkhus T, Brulois K, Dermadi D, Nordling S,
740 Vanlandewijck M, Jalkanen S, Ulvmar MH, Butcher EC. A Single-Cell
741 Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic
742 Vasculature. *Front Cardiovasc Med* 2020; 7: 52.
- 743 46. Kambouchner M, Bernaudin J-F. Intralobular pulmonary lymphatic distribution in normal
744 human lung using D2-40 antipodoplanin immunostaining. *Journal of Histochemistry*
745 *& Cytochemistry* 2009; 57: 643-648.
- 746 47. Bondareva O, Rodríguez-Aguilera JR, Oliveira F, Liao L, Rose A, Gupta A, Singh K,
747 Geier F, Schuster J, Boeckel JN, Buescher JM, Kohli S, Klötting N, Isermann B,

- 748 Blüher M, Sheikh BN. Single-cell profiling of vascular endothelial cells reveals
749 progressive organ-specific vulnerabilities during obesity. *Nat Metab.* 2022
750 Nov;4(11):1591-1610
- 751 48. Rodor J, Chen SH, Scanlon JP, Monteiro JP, Cadrillier A, Sweta S, Stewart KR,
752 Shmakova A, Dobie R, Henderson BEP, Stewart K, Hadoke PWF, Southwood M,
753 Moore SD, Upton PD, Morrell NW, Li Z, Chan SY, Handen A, Lafyatis R, de Rooij
754 LPMH, Henderson NC, Carmeliet P, Spiroski AM, Brittan M, Baker AH. Single-cell
755 RNA sequencing profiling of mouse endothelial cells in response to pulmonary
756 arterial hypertension. *Cardiovasc Res.* 2022 Aug 24;118(11):2519-2534.
- 757 49. Wang F, Ding P, Liang X, Ding X, Brandt CB, Sjöstedt E, Zhu J, Bolund S, Zhang L, de
758 Rooij LPMH, Luo L, Wei Y, Zhao W, Lv Z, Haskó J, Li R, Qin Q, Jia Y, Wu W,
759 Yuan Y, Pu M, Wang H, Wu A, Xie L, Liu P, Chen F, Herold J, Kalucka J, Karlsson
760 M, Zhang X, Helmig RB, Fagerberg L, Lindskog C, Pontén F, Uhlen M, Bolund L,
761 Jessen N, Jiang H, Xu X, Yang H, Carmeliet P, Mulder J, Chen D, Lin L, Luo Y.
762 Endothelial cell heterogeneity and microglia regulons revealed by a pig cell landscape
763 at single-cell level. *Nat Commun.* 2022 Jun 24;13(1):3620.
- 764 50. Bhatti F, Ball G, Hobbs R, Linens A, Munzar S, Akram R, Barber AJ, Anderson M,
765 Elliott M, Edwards M. Pulmonary surfactant protein a is expressed in mouse retina by
766 Müller cells and impacts neovascularization in oxygen-induced retinopathy. *Invest*
767 *Ophthalmol Vis Sci* 2014; 56: 232-242.
- 768 51. Colmorten KB, Nexoe AB, Sorensen GL. The Dual Role of Surfactant Protein-D in
769 Vascular Inflammation and Development of Cardiovascular Disease. *Front Immunol*
770 2019; 10: 2264.
- 771 52. Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial
772 progenitor cells: identity defined? *J Cell Mol Med.* 2009 Jan;13(1):87-102.

- 773 53. Abdelgawad ME, Desterke C, Uzan G, Naserian S. Single-cell transcriptomic profiling
774 and characterization of endothelial progenitor cells: new approach for finding novel
775 markers. *Stem Cell Res Ther.* 2021 Feb 24;12(1):145.
- 776 54. Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. *Nat*
777 *Commun* 2017; 8: 14361.
- 778 55. Gaikwad AV, Eapen MS, McAlinden KD, Chia C, Larby J, Myers S, Dey S, Haug G,
779 Markos J, Glanville AR. Endothelial to mesenchymal transition (EndMT) and
780 vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis.
781 *Expert Review of Respiratory Medicine* 2020; 14: 1027-1043.
- 782 56. Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to mesenchymal transition
783 (EndoMT) in the pathogenesis of human fibrotic diseases. *Journal of clinical*
784 *medicine* 2016; 5: 45.
- 785 57. Jia W, Wang Z, Gao C, Wu J, Wu Q. Trajectory modeling of endothelial-to-mesenchymal
786 transition reveals galectin-3 as a mediator in pulmonary fibrosis. *Cell Death Dis.* 2021
787 Mar 26;12(4):327
- 788 58. Durante MA, Kurtenbach S, Sargi ZB, Harbour JW, Choi R, Kurtenbach S, Goss GM,
789 Matsunami H, Goldstein BJ. Single-cell analysis of olfactory neurogenesis and
790 differentiation in adult humans. *Nat Neurosci* 2020; 23: 323-326.
- 791 59. Kumari R, Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence
792 associated secretory phenotype. *Frontiers in cell and developmental biology* 2021; 9:
793 485.
- 794 60. Barratt S, Millar A. Vascular remodelling in the pathogenesis of idiopathic pulmonary
795 fibrosis. *QJM: An International Journal of Medicine* 2014; 107: 515-519.
- 796 61. van Deursen JM. The role of senescent cells in ageing. *Nature* 2014; 509: 439-446.

- 797 62. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell
798 senescence in human atherosclerosis: role of telomere in endothelial dysfunction.
799 *Circulation* 2002; 105: 1541-1544.
- 800 63. Seals DR, Jablonski KL, Donato AJ. Ageing and vascular endothelial function in humans.
801 *Clin Sci (Lond)* 2011; 120: 357-375.
- 802 64. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. The ageing endothelium,
803 cardiovascular risk and disease in man. *Exp Physiol* 2009; 94: 317-321.
- 804 65. Ting KK, Coleman P, Zhao Y, Vadas MA, Gamble JR. The ageing endothelium. *Vasc*
805 *Biol* 2021; 3: R35-R47.
- 806 66. Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic
807 pulmonary fibrosis in US adults 18-64 years old. *Eur Respir J.* 2016;48(1):179-86.
- 808 67. Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an
809 overview. *Journal of clinical medicine* 2018; 7: 201.
- 810 68. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic
811 pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. *Am J Respir*
812 *Cell Mol Biol* 2011; 45: 1-15.
- 813 69. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between
814 idiopathic pulmonary fibrosis and vascular disease: a population-based study. *Am J*
815 *Respir Crit Care Med* 2008; 178: 1257-1261.
- 816 70. Nathan SD, Tapson VF, Elwing J, Rischard F, Mehta J, Shapiro S, Shen E, Deng C,
817 Smith P, Waxman A. Efficacy of Inhaled Treprostinil on Multiple Disease
818 Progression Events in Patients with Pulmonary Hypertension due to Parenchymal
819 Lung Disease in the INCREASE Trial. *Am J Respir Crit Care Med* 2022; 205: 198-
820 207.
- 821 71. Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ,
822 Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A,

- 823 Tapson VF. Inhaled treprostinil and forced vital capacity in patients with interstitial
824 lung disease and associated pulmonary hypertension: a post-hoc analysis of the
825 INCREASE study. *Lancet Respir Med* 2021; 9: 1266-1274.
- 826 72. Solari E, Marcozzi C, Ottaviani C, Negrini D, Moriondo A. Draining the Pleural Space:
827 Lymphatic Vessels Facing the Most Challenging Task. *Biology (Basel)* 2022; 11: 419
- 828 73. Zhang XY, Lu WY. Recent advances in lymphatic targeted drug delivery system for
829 tumor metastasis. *Cancer Biol Med* 2014; 11: 247-254.
- 830 74. Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to
831 treat. *Respir Res* 2019; 20: 205.
- 832 75. Raghu G, Rochweg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR,
833 Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L,
834 Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ. An
835 Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic
836 Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir
837 Crit Care Med* 2015; 192: e3-19.
- 838 76. Brownell R, Kaminski N, Woodruff PG, Bradford WZ, Richeldi L, Martinez FJ, Collard
839 HR. Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. *Am J
840 Respir Crit Care Med* 2016; 193: 1213-1218.
- 841 77. Krämer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in ingenuity
842 pathway analysis. *Bioinformatics* 2014; 30: 523-530.
- 843 78. González-Loyola A, Petrova TV. Development and aging of the lymphatic vascular
844 system. *Adv Drug Deliv Rev.* 2021;169: 63-78.

845

846 **Figure legends**

847

848 **Figure 1. Cell type-specific composition of ageing human lung tissues from donors and**
849 **IPF patients from two independent cohorts. (A)** Schematic of methodology for samples
850 integration and comprehensive data analysis. Selected data from two studies were grouped
851 into two cohorts (18 samples in total; see Table 1; [25, 27]) and subjected to quality control
852 (Additional file 2: Figures S1, 2B) and merging into an integrated Seurat V4 object for
853 subsequent analysis. The resolution was determined using the clustree R package, with 0.5
854 value used for this analysis and throughout the study to avoid over-clustering. Endothelial
855 cell (EC) clusters were identified using pan-endothelial and lymphatic-specific markers. 3192
856 blood vessel endothelial cells (BEC) and 659 lymphatic vessel endothelial cells (LEC) were
857 identified, and sub-clustered for their characterization and comparison in donor and IPF
858 samples. Full details can be found in Additional file 1: Detailed methods. **(B)** UMAP
859 representation of all cells and cell clusters from all 18 samples (pooled). Clusters were
860 numbered, annotated and labelled according to their detected gene markers. Specific details
861 about each cell population can be found in Additional file 2: Figure S2 and Additional file 3,
862 Table S1. Two clusters (LEC and BEC) are labelled with a red ellipse. **(C)** Heatmap of top ten
863 differentially expressed genes by cells in the cluster. Each column represents the average
864 expression for a cell, hierarchically grouped by cell type. Gene expression values are scaled
865 from 2 (yellow) to -2 (purple) across rows within each cell type. **(D)** Violin plots and density
866 plots representation of expression data for pan-EC and LEC-specific markers expression in
867 all identified clusters. Density plot expression values are scaled from between 0.04 and 1
868 (yellow – high expression) to 0 (purple – low expression). **(E)** Stacked bar chart of percentage
869 contribution of each cluster to total lung population, split by cohort and condition - donor or
870 fibrosis (IPF). Colour keys for cluster identity is the same as in **B**. Percent contributions of
871 3,192 BEC and 659 LEC to the total cell population in ageing human lung are shown with

872 *arrows*. Specific details for each cell population can be found in the Additional file 3: Table
873 S3. **(F)** UMAP representation of all cells and clusters from all 18 samples (pooled), split by
874 condition (donor or fibrosis) and labelled by cluster (top panel), or split by cohort and
875 labelled by condition (*blue* – donor; *red* – fibrosis; bottom panel). **(G)** Box and whiskers plots
876 of EC percentage all cell types in the lung (*left*) or blood or lymphatic endothelial cells (BEC
877 and LEC respectively) from total EC per sample in individual lung samples percentage from
878 all other cell types in individual lung samples (*right*), split by condition (*blue* – donor; *red* –
879 IPF/fibrosis). The lines within the boxes denotes the medians, the ‘box’ contains the 25th to
880 75th percentiles and the ‘whiskers’ mark the range of the data. Statistical analysis was done
881 using Shapiro-Wilk test ($p=0.162$ for donor and $p=0.367$ for fibrosis) and unpaired t-test ($p =$
882 0.139). Means \pm standard deviation (2.501 ± 1.407 for donor and 3.959 ± 2.388 for fibrosis).
883 UMAP - Uniform Manifold Approximation and Projection.

884

885 **Figure 2. Cell subtype-specific EC subpopulation composition of ageing human lung**
886 **blood vessel endothelial cell cluster from donors and IPF patients from two independent**
887 **cohorts.** To comprehensively decipher transcriptional signatures of ageing human lung blood
888 vessel endothelial cell (BEC) in IPF, we subtracted scRNAseq data for BEC ($n=3192$) from
889 the total lung cell populations from integrated dataset (two cohorts and both conditions, see
890 Figure 1A), and sub-clustered them. **(A)** UMAP representation of all cells and cell
891 subpopulations from BEC cluster (from all 18 pooled samples) which are presented in the
892 Figure 1. Subpopulations were labelled 0-11 according to their signatures (Additional file 2:
893 Figure S3). Note that, although subpopulations 1, 7 and 8 visually present with two potential
894 subgroups each on this UMAP, each of two subgroups are not significantly different from
895 each other in the described clustering parameters (Additional file 1: Detailed methods). In
896 subpopulation 1, this is likely to be due to the limitations of visualisation of 2D UMAP
897 compared to 3D UMAP, which shows as an individual cluster (see also Figure 2E, Additional

898 file 4: Video S1). In subpopulation 7 and 8, 3D UMAP reveals the shift of one subgroup
899 towards subpopulation zero (see also Figure 2E; Additional file 4: Video S1). **(B)** Heatmap of
900 top 10 differentially expressed genes (DEG) by subpopulation. Each column represents the
901 average expression for a cell, hierarchically grouped by condition (donor or fibrosis) and cell
902 type. Gene expression values are scaled from 2 (yellow) to -2 (purple) across rows within
903 each cell type. Specific details about each cell subpopulation can be found in Additional file
904 2: Figures S3 - 5, and Additional file 3: Table S4. All cell clusters can be separated with high
905 confidence (Additional file 3: Table S5). **(C, D)** The analysis of the top 10 DEG for each
906 subpopulation (120 in total) was performed alongside tests for expression of pan-EC and
907 LEC markers and using violin plots to test their subpopulation-specific expression for
908 determining their selection for inclusion (or not) in 10 signatures of ageing lung BEC
909 subpopulations. **(C)** Violin plots of expression of pan-endothelial and LEC markers in 12
910 identified BEC subpopulations. **(D)** Dot plots of 49 genes identified as differentially
911 expressed by the heatmap in B, plotted alongside pan-EC and LEC markers and control genes
912 for comparison, and used in annotation of 12 identified BEC subpopulations (see also
913 annotation summary presented in Figure 4). Note that 39 (marked in red) of 49 identified
914 subpopulation-specific DEG have not been previously assigned as markers of individual
915 generic subpopulations of ageing human lung BEC. **(E)** Representative lineage map in a form
916 of a three-dimensional (3D) UMAP generated by performing trajectory analysis using the R
917 package Slingshot. Plotted lines are trajectories representing predicted relationships between
918 12 identified BEC subpopulations. 3D video can be found Additional file 4: Video S1. **(F)**
919 Table of module scores (Additional file 1: Detailed methods) grouped by references from
920 which reference signatures were derived. Six studies from 2013-2021 include: (i) Gillich et
921 al., 2019 (ii) Vanlandewijck et al., 2019; (iii) Iso et al., 2013; (iv) Nukala et al., 2021; (v)
922 Ochiya et al., 2014; (vi) Herwig et al., 2016. Abbreviations: aCAP - aerocyte capillary; gCAP
923 - general capillary; large – large vessel; art- artery; CAP1 - capillary 1; CAP2 - capillary 2;

924 bronc – bronchial; S vein - systemic vein; P vein - pulmonary vein; Acap - aerocyte capillary;
925 Gcap - general capillary; PeriB – Peribronchial (Note that names given by the authors are
926 preserved). *Coral red* represents a subpopulation with positive score (above 0) for signature,
927 colour intensity is proportional to the score positivity. Additional information is available in
928 Additional file 1: Detailed methods, Annotation of BEC subpopulation. UMAP - Uniform
929 Manifold Approximation and Projection.

930

931 **Figure 3. Percentage contributions of blood endothelial cell subpopulations in donors**
932 **and IPF patients.** Quantitative analysis of percentage contribution of cells from each
933 subpopulation to total blood endothelial cell (BEC) population in ageing human lung from
934 healthy donors and IPF patients was conducted using Seurat v4. (A) UMAP of BEC split by
935 sample condition (donor or fibrosis). (B) Table detailing the number of cells per cluster, split
936 by condition. (C-D) Stacked bar charts of percentage contribution of each subpopulation to
937 total endothelial cell population split by condition for (C) total integrated dataset and (D)
938 cohort 1 (*left*) and cohort 2 (*right*). Cell numbers from each individual sample were analysed
939 using Multiple t test. $P < 0.05$ (*) was considered significant. UMAP - Uniform Manifold
940 Approximation and Projection.

941

942 **Figure 4. Annotation of subpopulations and relationship between them in donors and**
943 **IPF patients.** The profiling of markers of EC sub-types (Figure 2F, Additional file 2: Figures
944 S6, S7, S9), when combined with the expression of pan-EC and LEC markers (Figure 2C-D)
945 and sub-population-specific signatures identified in this study (based on expression pattern of
946 49 DEG; Figures 2D, Additional file 2: Figure S3), lung tissue sample collection locations
947 (Table 1), modules scores of association with bronchial or pulmonary circulatory networks
948 (Figure 2F, Additional file 2: Figure S9), EC differentiation status (Additional file 2: Figure
949 S12), IPF-related alterations in cell numbers (Figure 3), high expression of *IL6*, *SELE* and

950 *ICAMI* [21, 24]; Figure 2D), cell cycle analysis data (Additional file 2: Figure S8) and
951 findings from three-dimensional pseudo-time lineage analysis (Figure 2E, Additional file 4:
952 Video S1), formed the foundation for the annotation of 12 identified ageing human lung BEC
953 subpopulations with distinct transcriptional signatures (Note that in-depth description is
954 provided in Additional file 1: Detailed methods, Annotation of BEC subpopulations). (A)
955 Table summarizing the information taken into account for naming/annotating subpopulations,
956 including gene signatures, sample location by cohort, blood vessel circulatory networks
957 (bronchial and pulmonary) and cell numbers (by condition - donor or IPF/fibrosis). ^a Key
958 colour code for subpopulations is the same as in Figures 2 and 3. ^b Sample location (by
959 cohort) information corresponds to Table 1. DLP = distal lung parenchyma, LABS =
960 Longitudinal apical to basal segments. ^c Cell number dot plots corresponds to data in Figure
961 3. Signature genes include previously reported (blue; n=10) and *de novo* identified in our
962 study genes (red; n=39). (B) Dendrogram (cluster tree) and dot plot of subpopulations, based
963 on unsupervised hierarchical clustering of 12 subpopulations of ageing human lung BEC
964 from integrated total dataset, which was split into two separate objects by condition (donor on
965 the *left* and fibrosis on the *right*). Stratification into two groups termed “capillary” (or
966 “microvascular”) and “macrovascular” is based on distinct clustering of capillary sub-clusters
967 (3, 5, 7 and 8).

968

969 **Figure 5. Spatial validation of bronchial blood endothelial subpopulations in distal lung**
970 **by immunohistochemistry and quantitative high content image analysis. (A-B)** Dotplots
971 of quantitative analysis of percentage contribution of cells from bronchial subpopulation 2
972 and 7 to total blood endothelial cell (BEC) population in ageing human lung from healthy
973 donors (n=4) and IPF patients (n=4) from cohort 1 (Table 1) was conducted using Seurat v4.
974 Donor samples are shown in blue, fibrosis samples in coral red. (C) Masson’s trichrome and
975 (C, F) immunohistochemical staining for calcitonin receptor like receptor (CLR) was

976 conducted on formalin fixed paraffin embedded (FFPE) tissue sections of distal lung surgical
977 biopsy from a 58-year-old male patient with IPF (with confirmed histopathological pattern of
978 usual interstitial pneumonia) using our anti-human CLR antibody LN1436 [43]). (C) Images
979 of scanned full sections (scalebars represent 5000 μ m) and two enlarged regions of interest
980 (ROI) 1 and 2 (see full set in Additional file 2: Figure S16; scalebars represent 100 μ m).
981 Yellow dotted line represents peri-bronchial areas (between bronchi and alveolar regions) that
982 were analysed. Black dotted line represents example measurement of width of peri-bronchial
983 area (see Additional file 1: Detailed methods). Dot plots of quantitative analysis of (D) peri-
984 bronchial area width and (E) number of CLR-positive nuclei from 9 analysed ROI. (D-E)
985 Low degree fibrosis areas are shown in blue, high degree fibrosis areas in red. A cut off of
986 90 μ m for average peri-bronchial area width was used to determine high (> 90) and lower (<
987 90) degree fibrosis. Shapiro Wilcoxon normality test and Mann-Whitney U test were used to
988 analyse the data. P values are indicated at the top. Dotplots presenting: (D) quantification for
989 peri-bronchial areas width in μ m and (E) a number of CLR positive nuclei per mm² (venule
990 nuclei, *left*; capillary nuclei, *right*). (F) Two sections (S1 and S2) from the same distal lung
991 biopsy were used for quantitative high content Image J analysis. Individual bronchi were
992 identified within the total section under microscope and selected for downstream analysis
993 (Additional file 1: Detailed methods). Scale bars represent 5000 μ m. Indicated with red box
994 and enlarged to the right of each scanned section are two representative examples of bronchi
995 in individual sections (see full set in Additional file 2: Figure S17). Barcharts representing the
996 results of quantitative image analysis of: (G) total section areas in mm², (H) number of
997 bronchi per section and (I) percentage of CLR-positive nuclei in total section; all done for S1
998 and S2 sections. Colours for bronchial venules and capillaries match colours of ageing human
999 lung BEC subpopulations 2 and 7 presented throughout paper (see Figure 4A as an example).

1000

1001 **Figure 6. Comparative analysis of numbers of blood endothelial subpopulations in**
1002 **alveolar regions of distal lung in IPF by scRNAseq, immunohistochemistry and**
1003 **quantitative high content imaging. (A)** Dotplot, **(B)** scatterplot and **(C-D)** stacked bar
1004 charts of quantitative analysis of percentage contribution of cells from subpopulations 0, 2, 3,
1005 4, 6 and 8 to total blood endothelial cell (BEC) population in ageing human lung from
1006 healthy donors (n=4) and IPF patients (n=4) from cohort 1 (Table 1) was conducted using
1007 Seurat v4. **(A-B)** Donor samples are shown in blue, fibrosis samples - in coral red. **(B)**
1008 Pearson correlation analysis for percentage contribution of subpopulations zero vs
1009 subpopulation two in fibrosis samples. Line of best fit shown by grey dashed line. R -
1010 Pearson correlation coefficient. **(C)** Contribution of subpopulation zero and 2 to total BEC
1011 per sample coloured by subpopulation in fibrosis samples. Colours of ageing human lung
1012 BEC subpopulations match those presented throughout paper (see Figure 4A as an example).
1013 **(D)** Stacked bar chart showing percentage contribution of BEC subpopulation zero and
1014 combined alveolar BEC subpopulations 3, 4, 6 and 8, when analysed together as a “single
1015 alveolar pool”. Subpopulation zero is coloured by coral red, Subpopulations 3, 4, 6, 8 are
1016 coloured white. Data includes both donor and fibrosis samples. **(E)** Paired
1017 ridgeplots/histograms and dotplots of *PECAMI* expression in donor (left) and fibrosis (right)
1018 samples from cohort 1 (Table 1) was conducted using Seurat v4. *Top row*, (coral ridgeplot) -
1019 subpopulation zero *Middle row*, (light grey ridgeplot) - subpopulations 3, 4, 6 and 8
1020 combined, with insert reflecting data for individual subpopulations; with colours of ageing
1021 human lung BEC subpopulations matching those presented throughout paper (see Figure 4A
1022 as an example). *Bottom row*, (grey ridgeplot) - subpopulations zero, 3, 4, 6 and 8 combined
1023 into a “single alveolar pool”. Note that the ridgeplot and dotplot for this pool in IPF patients
1024 (right) representing the *PECAMI* mRNA expression profile in alveolar region in the lung
1025 tissue, with increased number of CLR-negative BEC when compared to donors (left). **(F-H)**
1026 Immunohistochemical staining for CD31 was conducted on formalin fixed paraffin embedded

1027 (FFPE) tissue sections of distal lung surgical biopsy from a 58-year old male patient with IPF
1028 (with confirmed histopathological pattern of usual interstitial pneumonia) using mouse
1029 monoclonal antibody clone JC/70A. **(F)** Two representative regions of interest (ROI; 1 and 2)
1030 of alveolar regions of distal lung that were used for quantification are presented (see full set
1031 in Additional file 2: Figure S18). *Left*, low degree fibrosis, *right*, high degree fibrosis.
1032 Scalebar represents 100µm. Black dashed line represents example measurement of width of
1033 alveolar area analysed (for full details, see Additional file 1: Detailed methods). Dot plots of
1034 quantitative analysis of **(G)** alveolar area thickness in µm and **(H)** proportion of CD31
1035 positive nuclei per mm² (left) and average DAB signal intensity per CD31 positive nuclei
1036 (right). Nonfibrotic alveoli samples are shown in blue and fibrotic alveoli samples - in coral
1037 red. Nine ROIs were analysed for both nonfibrotic and fibrotic alveoli. Statistical analysis
1038 was done using Shapiro Wilcoxon test and Mann-Whitney U test. P values are indicated at
1039 the top. Note that immunohistochemistry and quantitative high content imaging profiles **(H)**
1040 confirm those from scRNAseq data analysis **(E)**.

1041

1042 **Figure 7. Association of differentially expressed genes in ageing human lung blood**
1043 **vessel endothelial cell with specific signalling pathways and endothelial cell-relevant**
1044 **processes in IPF. (A)** An example of volcano plot of differentially expressed genes (DEG)
1045 (donor vs IPF/fibrosis) in blood endothelial cell (BEC) subpopulation zero. Volcano plots for
1046 other subpopulations can be found in the Additional file 2: Figure S19A. Statistical analysis
1047 was done using Shapiro Wilcoxon test and Wilcoxon rank sum test, with P value <0.05
1048 (dotted line indicates cut-off) considered significant. **(B)** Doughnut plot of DEG between
1049 donor and IPF/fibrosis for each subpopulation. Outer ring shows up-regulated genes and
1050 inner ring represents down-regulated genes, with table in the centre showing numbers of
1051 DEG per subpopulation. Clusters 9 and 10 were excluded from the analysis, as they contained
1052 too few cells to analyse between conditions. **(C)** Bar chart detailing the results of the

1053 Ingenuity Pathway Analysis (IPA) using Core expression analysis function [77] of
1054 statistically significant altered pathways using DEG from **B**. *Blue colour* represents a
1055 negative Z score (down), and *orange* represents a positive Z score (up). DEG from three
1056 subpopulations (4, 6 and 7) did not significantly associate with any pathways and from two
1057 others (9 and 10) had too few cells in the IPF group for analysis. IPA was performed as
1058 described in Additional file 1: Detailed methods. **(D, E)** Key colour code for subpopulations
1059 is the same as in panel **C** and in Figures 2-4. **(D)** Histograms (ridgeplot) of endothelial cells
1060 differentiation (n= 5), mesenchymal transition (n= 12), inflammation (n= 567), and
1061 vasodilation (n= 36) scores in all blood endothelial subpopulations in donors (*donor*) and IPF
1062 (*fibrosis*). Ridgeplots for senescence (n= 79), apoptosis (n= 161), proliferation (n= 54),
1063 migration (n= 175), angiogenesis (n= 48), and permeability (n= 40) can be found in
1064 Additional file 2: Figure S20. Number of genes in sets are indicated in brackets. Black dotted
1065 line is added to annotate zero (cut-off point for differences). **(E)** Table detailing the P values
1066 for difference in module scores between donor and fibrosis. *Blue* colour represents down-
1067 regulation and *orange* - up-regulation in IPF. Statistical analysis was done using Shapiro
1068 Wilcoxon test and Mann-Whitney U test. UMAP - Uniform Manifold Approximation and
1069 Projection.

1070

1071 **Figure 8. Cell subtype-specific composition of ageing human lung lymphatic endothelial**
1072 **cell cluster from donors and IPF patients from two independent cohorts.** To
1073 comprehensively decipher transcriptional signatures of ageing human lung lymphatic vessel
1074 endothelium in IPF, we subtracted scRNAseq data for ageing human lung lymphatic vessel
1075 endothelial cell (LEC) (n=659) from the total lung cell populations from integrated dataset
1076 (two cohorts and both conditions, see Figure 1A), and sub-clustered them. **(A) Top**, UMAP
1077 representation of all cells from total LEC cluster/population (from all 18 pooled samples;
1078 Figure 1) with pseudotime lineage analysis of 5 resulting subclusters. *Bottom*, UMAP of LEC

1079 clusters coloured by cohort. Clusters were labelled 0-4 according to their signatures, which
1080 are presented as **(B)** heatmap of top 5 differentially expressed genes by cluster. Full details
1081 about each cell sub-population can be found in Additional file 2: Figure S21-23. **(C)** Violin
1082 plots demonstrating expression of pan-EC markers and LEC-specific genes (*PROX1*, *PDPN*,
1083 *LYVE-1* and *FLT4*) and *CCL21* [78] was done to confirm the identities of all cell
1084 subpopulations as LEC. **(D)** Table summarizing the information for each subpopulation,
1085 including gene signature (including previously reported, in *blue*, and *de novo* identified in our
1086 study, in *red*, genes), sample location by cohort and cell numbers. ^a Key colour code for
1087 subpopulations is the same as in Figure 8A. ^b Sample location (by cohort) information
1088 corresponds to Table 1. DLP = distal lung parenchyma, LABS = Longitudinal apical to basal
1089 segments. ^c Cell number dot plots correspond to data in Additional file 2: Figure S24 A, B.
1090 **(E)** Dotplot of quantification for percentage contribution of subpopulation 1 and 2 to total
1091 LEC per sample. *Left*, subpopulation 1, *right*, subpopulation 2. Donor samples are shown in
1092 blue, fibrosis samples - in coral red. **(F-H)** Immunohistochemical staining for PDPN was
1093 conducted on formalin fixed paraffin embedded (FFPE) tissue sections of distal lung surgical
1094 biopsy from a 58-year-old male patient with IPF (with confirmed histopathological pattern of
1095 usual interstitial pneumonia) using mouse monoclonal antibody clone D2-40. **(F)** Image of
1096 scanned full section (scalebars represent 5000µm), with six regions of interest (ROI) 1-6
1097 labelled with red boxes and shown enlarged in **(G)** (scalebars represent 100µm). Table insert
1098 to the right is the summary of information for each ROI on whether observed structure could
1099 be identified in original publications for cohorts 1 and 2 (^{*} - [25, 27]), i.e. DLP and LABS
1100 areas of the lung respectively (see **D**), and which LEC subpopulations were detected in our
1101 analysis (see **A**). **(G)** |Representative images for each ROI (magnified from **F**; scalebars
1102 represent 100µm), including inserts (red dotted boxes) of the areas containing PDPN-positive
1103 lymphatic vessels (*bottom right*; scalebars represent 100µm). Coloured squares in the top left
1104 corner correspond to mapping conducted using table presented in **(F)**. Arrows - lymphatic

1105 vessel; A - artery; V – vein; Arrowhead - small vessel; * - honeycomb cysts; B – bronchioles;
1106 P - pleura. **(H)** Dot plots of quantitative analysis of percentage of PDPN-positive nuclei from
1107 all identifiable nuclei per mm² within individual ROI (n=3 per ROI), grouped by location
1108 within distal lung diagnostic biopsy of IPF (for full details, see Additional file 1: Detailed
1109 methods; images of 21 ROI used for high content image analysis are presented in Additional
1110 file 2: Figure S25). **(I)** Doughnut plot of DEG between donor and IPF/fibrosis for each
1111 subpopulation. Ring shows up-regulated genes, with table in the centre showing numbers of
1112 DEG per subpopulation (see also Additional file 3: Table S10). Note that no downregulated
1113 genes were found for LEC subpopulations. **(J)** Table detailing the P values for difference in
1114 module scores between donor and fibrosis. *Blue* colour represents down-regulation and
1115 *orange* – up-regulation in IPF. Statistical analysis was done using Shapiro Wilcoxon test and
1116 Mann-Whitney U test. UMAP - Uniform Manifold Approximation and Projection.

TABLES

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Table 1. Characteristics of aging human lung tissue samples split by cohort.

Cohort 1 (8 samples) was from GSE122960_RAW (Reyfan et al., 2019) and cohort 2 (10 samples) was from GSE136831 (Adams et al., 2020). M = male, F = female, IPF = idiopathic pulmonary fibrosis, N/A = not applicable.

Cohort 1

Sample ID	Age (yr)	Sex	Race	Diagnosis	Sample location	Number of cells
D1	63	F	African american	N/A		6951
D2	55	M	Asian	N/A	1-2 cm distal lung	6625
D4	57	F	African american	N/A	parenchyma	9843
D5	49	F	White	N/A		9108
IPF 1	66	M	Unknown	IPF		4872
IPF 2	60	M	Unknown	IPF	1-2 cm distal lung	3670
IPF 3	68	M	Unknown	IPF	parenchyma	11035
IPF 4	72	F	Unknown	IPF		5940


Cohort 2

Sample ID	Age (yr)	Sex	Race	Diagnosis	Sample location	Number of cells
439C	66	F	White	N/A		9198
065C	66	F	White	N/A	Longitudinal	2403
388C	61	M	White	N/A	biopsies from apical	3088
192C	62	F	White	N/A	to most basal	5002
160C	64	M	White	N/A	segments of the lung	3981
221I	67	M	White	IPF		6931
222I	59	M	White	IPF	Longitudinal	10354
021I	69	M	White	IPF	biopsies from apical	4090
29I	61	M	White	IPF	to most basal	1335
0631I-b	68	M	White	IPF	segments of the lung	4419


FIGURE 1

A


medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




B




C




D



E



F



G








FIGURE 2

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




F

BEC sub-populations	Signatures																								
	Six studies 2013-2021					Travaglini et al., 2020					Adams et al., 2020				Schupp et al., 2021				Sauler et al., 2022						
	Artery	Vein	gCAP	sCAP	Large	Art	Vein	CAP1	CAP2	Bronc	Artery	Vein	Capillary A	Capillary B	Peribronchial	Artery	S vein	P vein	Acap	Gcap	Artery	Vein	sCAP	gCAP	PeriB
0	-0.045	0.024	-0.234	0.185	0.103	0.018	-0.148	0.231	-0.197	-0.123	-0.003	-0.053	0.045	0.081	-0.156	0.001	-0.102	-0.081	0.123	0.043	-0.070	-0.051	0.163	0.736	-0.179
1	-0.104	-0.113	-0.368	-0.173	-0.099	-0.189	0.586	-0.170	-0.591	-0.035	-0.069	-0.164	-0.151	-0.276	0.635	-0.103	0.151	-0.014	-0.193	-0.349	-0.218	0.302	-0.612	-0.054	0.066
2	-0.144	0.196	-0.511	-0.194	-0.038	-0.139	0.878	-0.066	-0.631	0.372	-0.115	-0.023	-0.190	-0.172	0.549	-0.085	0.226	0.162	-0.162	-0.380	-0.323	0.383	-0.639	-0.077	0.280
3	0.001	-0.093	0.689	0.004	0.061	-0.057	-0.267	-0.039	0.869	-0.369	-0.065	-0.238	0.170	0.700	-0.294	-0.050	-0.293	-0.276	-0.015	0.807	-0.266	-0.160	0.166	1.967	-0.344
4	0.495	-0.046	-0.468	-0.182	-0.054	0.884	-0.434	-0.105	-0.544	-0.131	0.559	-0.071	-0.272	0.039	-0.409	0.583	-0.312	-0.139	-0.183	-0.274	0.912	-0.249	-0.634	0.513	-0.338
5	-0.035	-0.055	-0.015	0.012	0.083	-0.064	0.159	0.047	-0.100	-0.105	-0.043	-0.115	-0.008	-0.042	0.080	-0.039	-0.050	-0.053	0.033	0.010	-0.134	-0.034	-0.127	0.249	-0.102
6	-0.163	1.057	-0.113	-0.185	0.002	-0.119	1.379	-0.102	-0.079	0.080	0.043	0.636	-0.208	0.404	0.163	-0.088	-0.117	0.789	-0.142	-0.089	-0.319	0.776	-0.551	0.937	-0.182
7	-0.116	-0.027	-0.390	-0.055	0.028	-0.159	0.275	0.004	-0.491	0.123	-0.099	-0.127	-0.164	-0.050	0.221	-0.071	-0.016	-0.108	-0.114	-0.148	-0.215	0.112	-0.429	0.307	0.089
8	-0.163	-0.195	-0.166	1.013	0.283	-0.131	-0.364	0.856	-0.207	-0.393	-0.145	-0.176	0.627	-0.023	-0.418	-0.139	-0.263	-0.229	0.887	-0.103	-0.292	-0.260	1.503	0.652	-0.405
9	-0.116	0.414	-0.406	-0.121	0.271	-0.126	1.091	-0.101	-0.390	0.251	0.048	0.377	-0.200	-0.067	0.491	-0.054	0.036	0.527	-0.135	-0.256	-0.233	0.867	-0.459	0.323	-0.085
10	-0.130	-0.152	-0.609	-0.078	-0.014	-0.096	-0.531	0.004	-0.578	-0.275	-0.074	-0.257	-0.237	-0.442	-0.426	-0.052	-0.296	-0.195	-0.086	-0.270	-0.218	-0.287	-0.473	-0.009	-0.470
11	-0.140	-0.163	-0.307	-0.155	0.373	-0.059	-0.170	-0.118	-0.382	-0.280	-0.094	-0.202	-0.198	-0.226	-0.297	-0.116	-0.225	-0.215	0.064	-0.162	-0.194	-0.167	-0.379	0.208	-0.377

FIGURE 3


medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

A



BEC sub-populations	Cell numbers, n (%)	
	Donor	Fibrosis
0	577 (29.3)	124 (10.1)
1	70 (3.5)	352 (28.8)
2	51 (2.6)	367 (30)
3	316 (16)	29 (2.4)
4	209 (10.6)	51 (4.2)
5	87 (4.4)	161 (13.2)
6	166 (8.4)	19 (1.6)
7	145 (7.4)	34 (2.8)
8	100 (5.1)	68 (5.6)
9	136 (6.9)	3 (0.3)
10	63 (3.2)	2 (0.2)
11	50 (2.5)	12 (1)

C



D




FIGURE 4

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

A

KEY ^a	Number	BEC subpopulations		Cohort (location) ^b		Circulation		Cell numbers ^c	
		Annotation	Genes	DLP	LABS	Bronchial	Pulmonary	Donor	Fibrosis
	0	De-differentiated	Negativity for all markers and low expression of pan-endothelial EC markers					●	●
	1	Bronchial venule (IPF Endo 1)	<i>ADAMTS9, ADAMTS9-AS1, TLL1, ABCB1, CMAHP, MTND412, FAM155A</i>					●	●
	2	Bronchial venule (IPF Endo 2)	<i>SPRY1, IGCK, IGLC2, IGHG4</i>					●	●
	3	General capillary (gCAP)	<i>SLC6A4, CD36, FCN3</i>					●	●
	4	Intralobular arteriole	<i>DKK2, GJA5, EFN2, HEY1, IGFBP3</i>					●	●
	5	De-differentiated capillary	Negativity for all markers and low expression of pan-endothelial EC markers					●	●
	6	Intralobular venule	<i>PTGDS, RAMP3, SULT1E1, TAGLN, C7</i>					●	●
	7	Bronchial capillary	<i>ANGPT2, HISPA1B, CD34</i>					●	●
	8	Aerocyte (aCAP)	<i>AFF3, IL1RL1, PRKG1, NCALD, HPGD</i>					●	●
	9	Inflammatory	<i>IL6, SELE, ICAM1</i>					●	●
	10	Pneumocyte marker (low) expressing	<i>NAPSA, SFTPB, SFTPA1, SLPI, SFTPA2, PGC</i>					●	●
	11	Immune marker (low) expressing	<i>HLA-DPB1, C1QB, HLA-DRA, C1QA, C1QC, ALOX5AP, LYZ, TYROBP</i>					●	●

B




FIGURE 5

A medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).






FIGURE 6


A




B




C




D




E



F



G



H




FIGURE 8

medRxiv preprint doi: <https://doi.org/10.1101/2022.03.08.22272025>; this version posted April 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

